Summary and future of medicine for hereditary angioedema

被引：2
作者：
Ding, Lei
Zhang, Meng-Jiao
Rao, Guo-Wu [1 ]
机构：
[1] Zhejiang Univ Technol, Coll Pharmaceut Sci, Hangzhou 310014, Peoples R China
来源：
DRUG DISCOVERY TODAY | 2024年 / 29卷 / 03期
关键词：
Hereditary angioedema; Pathogenesis; C1; inhibitor; Drugs; C1 ESTERASE INHIBITOR; CONESTAT ALPHA; ACUTE ATTACKS; KALLIKREIN INHIBITOR; PLASMIN INHIBITORS; ECALLANTIDE; DEFICIENCY; MANAGEMENT; CONCENTRATE; EFFICACY;
D O I：
10.1016/j.drudis.2024.103890
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Hereditary angioedema (HAE) is a rare autosomal genetic disease for which there are currently nine FDA-approved drugs. This review summarizes drug treatments for HAE based on four therapeutic pathways: inhibiting the contact system, inhibiting bradykinin binding to B2 receptors, supplying missing C1 inhibitors, and inhibiting plasminogen conversion. The review generalizes the clinical use, pharmacological effects and mechanisms of HAE drugs, and it also discusses possible development directions and targets to enhance understanding of HAE and help researchers.
引用
收藏
页数：9
相关论文
共 70 条
[1]   Recent Advances on Plasmin Inhibitors for the Treatment of Fibrinolysis-Related Disorders [J].
Al-Horani, Rami A. ;
Desai, Umesh R. .
MEDICINAL RESEARCH REVIEWS, 2014, 34 (06) :1168-1216
[2]   Hereditary angioedema: a current state-of-the-art review, V: attenuated androgens for the treatment of hereditary angioedema [J].
Banerji, Aleena ;
Sloane, David E. ;
Sheffer, Albert L. .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2008, 100 (01) :S19-S22
[3]   Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study [J].
Banerji, Aleena ;
Bernstein, Jonathan A. ;
Johnston, Douglas T. ;
Lumry, William R. ;
Magerl, Markus ;
Maurer, Marcus ;
Martinez-Saguer, Inmaculada ;
Zanichelli, Andrea ;
Hao, James ;
Inhaber, Neil ;
Yu, Ming ;
Riedl, Marc A. .
ALLERGY, 2022, 77 (03) :979-990
[4]   Hereditary angioedema: Classification, pathogenesis, and diagnosis [J].
Banerji, Aleena .
ALLERGY AND ASTHMA PROCEEDINGS, 2011, 32 (06) :403-407
[5]   Current treatment of hereditary angioedema: An update on clinical studies [J].
Banerji, Aleena .
ALLERGY AND ASTHMA PROCEEDINGS, 2010, 31 (05) :398-406
[6]   New and evolving therapies for hereditary angioedema [J].
Barmettler, Sara ;
Li, Yu ;
Banerji, Aleena .
ALLERGY AND ASTHMA PROCEEDINGS, 2019, 40 (01) :7-13
[7]   Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability [J].
Bernstein, Jonathan A. ;
Qazi, Momina .
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2010, 6 (01) :29-39
[8]   Side effects of long-term treatment with danazol and stanozolol in hereditary Angioedema [J].
Bork, K. ;
Zingale, L. ;
Farkas, H. ;
Bygum, A. ;
Bouillet, L. ;
Bucher, C. ;
Caballero, T. ;
Longhurst, H. ;
Nielsen, E. ;
Cicardi, M. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (01) :S275-S275
[9]   Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report [J].
Bork, Konrad ;
Anderson, John T. ;
Caballero, Teresa ;
Craig, Timothy ;
Johnston, Douglas T. ;
Li, H. Henry ;
Longhurst, Hilary J. ;
Radojicic, Cristine ;
Riedl, Marc A. .
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2021, 17 (01)
[10]   A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE) [J].
Bork, Konrad .
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2016, 51 (02) :183-192
1234567